Effects of Glucagon-Like Peptide-1 and Long-Acting Analogues on Cardiovascular and Metabolic Function

Author： Saraceni Christine   Broderick Tom L.  

Publisher： Adis International

ISSN： 1174-5886

Source： Drugs in R&D, Vol.8, Iss.3, 2007-01, pp. : 145-153

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

NN2211: a long-acting glucagon-like peptide-1 derivative with anti-diabetic effects in glucose-intolerant pigs

By Ribel U.   Larsen M.O.   Rolin B.   Carr R.D.   Wilken M.   Sturis J.   Westergaard L.   Deacon C.F.   Knudsen L.B.  

European Journal of Pharmacology, Vol. 451, Iss. 2, 2002-09 ,pp. : 217-225

Elsevier

Access to resources Recommend Favorite

Cardiovascular Effects of Glucagon-Like Peptide 1

By  

Mini Reviews in Medicinal Chemistry, Vol. 11, Iss. 1, 2011-01 ,pp. : 97-105

Bentham Science Publishers

Access to resources Recommend Favorite

Taspoglutide: a long acting human glucagon-like polypeptide-1 analogue

By Retterstøl Kjetil  

Expert Opinion on Investigational Drugs, Vol. 18, Iss. 9, 2009-09 ,pp. : 1405-1411

Informa Healthcare

Access to resources Recommend Favorite

Developments of Glucagon Like Peptide-1 (GLP-1) and Long-acting Analogs in Clinical and Preclinical Studies for Treatment of Type 2 Diabetes

By  

Current Pharmaceutical Biotechnology, Vol. 14, Iss. 9, 2013-10 ,pp. : 835-841

Bentham Science Publishers

Access to resources Recommend Favorite

Glucagon-like Peptide-1 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents

By Gallwitz Baptist  

Drugs, Vol. 71, Iss. 13, 2011-09 ,pp. : 1675-1688

Adis International

Access to resources Recommend Favorite